Active, not recruitingPHASE1, PHASE2NCT03930953

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Studying Hodgkin lymphoma

Last synced from ClinicalTrials.gov May 14, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Celgene
Principal Investigator: Bristol-Myers Squibb
Bristol-Myers Squibb
Intervention: CC-99282(drug)
Enrollment: 438 enrolled
Eligibility: 18 years · All sexes
Timeline: 2019 – 2028

Study locations (30)

Local Institution - 109, Scottsdale, Arizona, United States
Local Institution - 111, Jacksonville, Florida, United States
Local Institution - 102, Tampa, Florida, United States
Local Institution - 108, Overland Park, Kansas, United States
Local Institution - 107, Rochester, Minnesota, United States
Local Institution - 104, St Louis, Missouri, United States
Local Institution - 103, Hackensack, New Jersey, United States
Local Institution - 101, Houston, Texas, United States
Local Institution - 255, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 254, Pilar, Buenos Aires, Argentina
Local Institution - 253, Buenos Aires, Argentina
Local Institution - 701, Salzburg, Austria
Local Institution - 704, Sankt Pölten, Austria
Local Institution - 703, Vienna, Austria
Local Institution - 902, Leuven, Belgium
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03930953 on ClinicalTrials.gov

Other trials for Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Hodgkin lymphoma →

← Back to all trials